Because of reports of occasional objective responses in renal cell carcinoma with chlorozotocin in phase I studies and reported activity of CCNU in this disease, the present phase II study was initiated. Twenty-one patients with histologically confirmed unresectable renal cell carcinoma were entered in this study between June 1977 and February 1978. No significant tumor regression occurred in the 21 chlorozotocin-treated patients. The treatment group included patients with a good PS who experienced myelosuppression secondary to chlorozotocin. In addition, 14 of 21 (67%) of the patients had received no prior hormonal or myelosuppressive chemotherapy. Because no PRs were achieved in this number of patients, it can be concluded that chlorozotocin is likely to have a true major response rate of <15%. The drug would appear to have little therapeutic value in this schedule as a single agent in patients with advanced renal cell carcinoma.
|Original language||English (US)|
|Number of pages||2|
|Journal||Cancer Treatment Reports|
|State||Published - Dec 1 1979|
ASJC Scopus subject areas
- Cancer Research